Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies

Sarah L Scarpace

Article Type

Review

Published

Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. This paper provides an overview of drug therapy options for squamous cell NSCLC with a focus on the evidence and clinical application of the anti-PD1 therapies. A comparison of the dosing, administration, indications, and differences in the measurement of PD-L1 expression in the clinical trials of nivolumab and pembrolizumab is also provided.

Read more

Antidepressant efficacy and side-effect burden: a quick guide for clinicians

Daniel Santarsieri, Thomas L Schwartz

Article Type

Review

Published

Prescribing of antidepressant treatment (ADT) for major depressive disorder (MDD) has increased substantially over the last two decades. In this paper, the authors discuss the evidence that supports the use of ADT based on FDA approvals, data from randomized controlled trials or meta-analyses and where these are not available, the authors discuss and apply theoretical pharmacodynamic principles to help guide treatment choice in MDD.

Read more

Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder

Molly R Belkin, Thomas L Schwartz

Article Type

Review

Published

Posttraumatic stress disorder (PTSD) is thought to be related to a hyperactive sympathetic nervous system. Sometimes, use of the US Food and Drug Administration (FDA)-approved medications for PTSD, the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine, may not lead to full remission and symptoms of hyperarousal may persist. In this article the authors review the literature on the alpha-2 receptor agonists clonidine and guanfacine for the treatment of PTSD and conclude that while the evidence base is limited, these agents might be considered useful when SSRIs fail in patients with PTSD.

Read more

Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome

Pavel Gershokovich, Kishor M Wasan, Charles Ribeyre, Fady Ibrahim, John H McNeill

Article Type

Case Report

Published

Benzodiazepines (BDZ) are the drugs of choice to prevent the symptoms of alcohol withdrawal syndrome (AWS). Differences in treatment regimens, the choice of BDZ, as well as the presence of liver cirrhosis can substantially alter the exposure of patients to drugs used for AWS treatment so patients should be carefully monitored.

Read more

A review of current treatment strategies for gestational diabetes mellitus

Kristi W Kelley, Dana G Carroll, Allison Meyer

Article Type

Review

Published

Once changes in lifestyle have failed, treatment for gestational diabetes mellitus remains a matter of debate. In this article the authors review the evidence for glyburide and metformin, and discuss the role of insulin. Also, recommendations for postpartum screening and how to manage patients who are breastfeeding are described.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.